Outcomes following cardiac intensive care unit (CICU) admission are influenced by many factors including initial cardiac diagnosis, surgical complexity, and burden of critical illness. Additionally, the presence of noncardiac issues may have a significant impact on outcomes and the patient experience during and following an intensive care unit stay. This review focuses on three common noncardiac areas which impact outcomes and patient experience in and beyond the CICU: feeding and growth, pain and analgesia, and anticoagulation. Growth failure and feeding dysfunction are commonly encountered in infants requiring cardiac surgery and have been associated with worse surgical and developmental outcomes. Recent studies most notably in the single ventricle population have demonstrated improved weight gain and outcomes when feeding protocols are implemented. Children undergoing cardiac surgery may experience both acute and chronic pain. Emerging research is investigating the impact of sedatives and analgesics on neurodevelopmental outcomes and quality of life. Improved pain scores and standardized management of pain and withdrawal may improve the patient experience and outcomes. Effective anticoagulation is a critical component of perioperative care but may be complicated by inflammation, multiorgan dysfunction, and patient factors. Advances in monitoring of anticoagulation and emerging therapies are reviewed.
RudolfMCLoganS. What is the long term outcome for children who fail to thrive? A systematic review. Arch Dis Child. 2005;90(9):925–931.
2.
BlackMMDubowitzHKrishnakumarAStarrRHJr. Early intervention and recovery among children with failure to thrive: follow-up at age 8. Pediatrics. 2007;120(1):59–69.
3.
DykmanRACaseyPHAckermanPTMcPhersonWB. Behavioral and cognitive status in school-aged children with a history of failure to thrive during early childhood. Clin Pediatr (Phila). 2001;40(2):63–70.
4.
BlockRWKrebsNF. Failure to thrive as a manifestation of child neglect. Pediatrics. 2005;116(5):1234–1237.
5.
RadmanMMackRBarnoyaJ. The effect of preoperative nutritional status on postoperative outcomes in children undergoing surgery for congenital heart defects in San Francisco (UCSF) and Guatemala City (UNICAR). J Thorac Cardiovasc Surg. 2014;147(1):442–450.
6.
LeiteHPFisbergMde CarvalhoWBde Camargo CarvalhoAC. Serum albumin and clinical outcome in pediatric cardiac surgery. Nutrition. 2005;21(5):553–558.
7.
AndersonJBKalkwarfHJKehlJEEghtesadyPMarinoBS. Low weight-for-age z-score and infection risk after the Fontan procedure. Ann Thorac Surg. 2011;91(5):1460–1466.
8.
CohenMSZakVAtzAM. Anthropometric measures after Fontan procedure: implications for suboptimal functional outcome. Am Heart J. 2010;160(6):1092–1098.
9.
DavisDDavisSCotmanK. Feeding difficulties and growth delay in children with hypoplastic left heart syndrome versus d-transposition of the great arteries. Pediatr Cardiol. 2008;29(2):328–333.
10.
KelleherDKLaussenPTeixeira-PintoADugganC. Growth and correlates of nutritional status among infants with hypoplastic left heart syndrome (HLHS) after stage 1 Norwood procedure. Nutrition. 2006;22(3):237–244.
11.
VogtKNManlhiotCVan ArsdellGRussellJLMitalSMcCrindleBW. Somatic growth in children with single ventricle physiology impact of physiologic state. J Am Coll Cardiol. 2007;50(19):1876–1883.
NatarajanGReddyASAggarwalS. Enteral feeding of neonates with congenital heart disease. Neonatology. 2010;98(4):330–336.
17.
HehirDARuddNMussattoKA. Normal interstage growth after the Norwood operation is associated with interstage home monitoring. Pediatr Cardiol. 2012;33(8):1315–1322.
18.
WillisLThureenPKaufmanJWymoreESkillmanHda CruzE. Enteral feeding in prostaglandin-dependent neonates: is it a safe practice?J Pediatr. 2008;153(6):867–869.
19.
JeffriesHEWellsWJStarnesVAWetzelRCMoromisatoDY. Gastrointestinal morbidity after Norwood palliation for hypoplastic left heart syndrome. Ann Thorac Surg. 2006;81(3):982–987.
20.
HillGDSilvermanAHNoelRJ. Feeding dysfunction in children with single ventricle following staged palliation. J Pediatr. 2014;164(2):243–246.
21.
SkinnerMLHalsteadLARubinsteinCSAtzAMAndrewsDBradleySM. Laryngopharyngeal dysfunction after the Norwood procedure. J Thorac Cardiovasc Surg. 2005;130(5):1293–1301.
22.
AndersonJBBeekmanRH IIIBorderWL. Lower weight-for-age z score adversely affects hospital length of stay after the bidirectional Glenn procedure in 100 infants with a single ventricle. J Thorac Cardiovasc Surg. 2009;138(2):397–404.
23.
SiehrSLNorrisJKBushnellJA. Home monitoring program reduces interstage mortality after the modified Norwood procedure. J Thorac Cardiovasc Surg. 2014;147(2):718–723.
24.
FurckAKUebingAHansenJH. Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: a 12-year single-center survey. J Thorac Cardiovasc Surg. 2010;139(2):359–365.
25.
PetitCJFraserCDMattamalRSlesnickTCCephusCEOcampoEC. The impact of a dedicated single-ventricle home-monitoring program on interstage somatic growth, interstage attrition, and 1-year survival. J Thorac Cardiovasc Surg. 2011;142(6):1358–1366.
26.
KuglerJDBeekman IiiRHRosenthalGL. Development of a pediatric cardiology quality improvement collaborative: from inception to implementation. From the Joint Council on Congenital Heart Disease Quality Improvement Task Force. Congenit Heart Dis. 2009;4(5):318–328.
27.
Medoff-CooperBIrvingSYMarinoBS. Weight change in infants with a functionally univentricular heart: from surgical intervention to hospital discharge. Cardiol Young. 2011;21(2):136–144.
28.
SrinivasanCJaquissRDMorrowWR. Impact of staged palliation on somatic growth in patients with hypoplastic left heart syndrome. Congenit Heart Dis. 2010;5(6):546–551.
29.
HongBJMoffettBPayneWRichSOcampoECPetitCJ. Impact of postoperative nutrition on weight gain in infants with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2014;147(4):1319–1325.
30.
LiJZhangGHerridgeJ. Energy expenditure and caloric and protein intake in infants following the Norwood procedure. Pediatr Crit Care Med. 2008;9(1):55–61.
31.
RogersEJGilbertsonHRHeineRGHenningR. Barriers to adequate nutrition in critically ill children. Nutrition. 2003;19(10):865–868.
32.
GiannonePJLuceWANankervisCAHoffmanTMWoldLE. Necrotizing enterocolitis in neonates with congenital heart disease. Life Sci. 2008;82(7-8):341–347.
33.
LeungMPChauKTHuiPW. Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. J Peds. 1988;113(6):1044–1046.
34.
McElhinneyDBHedrickHLBushDM. Necrotizing enterocolitis in neonates with congenital heart disease: risk factors and outcomes. Pediatrics. 2000;106(5):1080–1087.
35.
MukherjeeDZhangYChangDCVricellaLABrennerJIAbdullahF. Outcomes analysis of necrotizing enterocolitis within 11,958 neonates undergoing cardiac surgical procedures. Arch Surg. 2010;145(4):389–392.
36.
BellMJ. Neonatal necrotizing enterocolitis. N Engl J Med. 1978;298(5):281–282.
37.
del CastilloSLMcCulleyMEKhemaniRG. Reducing the incidence of necrotizing enterocolitis in neonates with hypoplastic left heart syndrome with the introduction of an enteral feed protocol. Pediatr Crit Care Med. 2010;11(3):373–377.
38.
KaufmanJAlmodovarMCZukJFriesenRH. Correlation of abdominal site near-infrared spectroscopy with gastric tonometry in infants following surgery for congenital heart disease. Pediatr Crit Care Med. 2008;9(1):62–68.
39.
BraudisNJCurleyMABeaupreK. Enteral feeding algorithm for infants with hypoplastic left heart syndrome poststage I palliation. Pediatr Crit Care Med. 2009;10(4):460–466.
40.
Pillo-BlockaFAdatiaISharieffWMcCrindleBWZlotkinS. Rapid advancement to more concentrated formula in infants after surgery for congenital heart disease reduces duration of hospital stay: a randomized clinical trial. J Pediatr. 2004;145(6):761–766.
41.
Thull-FreedmanJ. Evaluation of chest pain in the pediatric patient. Med Clin North Am. 2010;94(2):327–347.
42.
SolanoJPGomesBHigginsonIJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.
43.
MarinoBSTomlinsonRSWernovskyG. Validation of the pediatric cardiac quality of life inventory. Pediatrics. 2010;126(3):498–508.
TwiteMDRashidAZukJFiesenRH. Sedation, analgesia, and neuromuscular blockade in the pediatric intensive care unit: survey of fellowship training programs. Pediatr Crit Care Med. 2004;5:521–532.
46.
TaylorEMBoyerKCampbellFA. Pain in hospitalized children: a prospective cross-sectional survey of pain prevalence, intensity, assessment and management in a Canadian pediatric teaching hospital. Pain Res Manag. 2008;13(1):25–32.
47.
StaveskiSLLincolnPAFinemanLDAsaroLAWypijD, Nurse decision making regarding the use of analgesics and sedatives in the Pediatric Cardiac ICU. Pediatr Crit Care Med. 2014;15(8):691–697.
AnandKJHickeyPR. Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N Engl J Med. 1992;326(1):1–9.
50.
EasleyRBTobiasJD. Pro: dexmedetomidine should be used for infants and children undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22(1):147–151.
51.
ChrysostomouCDi FilippoSManriqueAM. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med. 2006;7(2):126–131.
52.
MukhtarAMObayahEMHassonaAM. The use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg. 2006;103(1):52–56.
53.
AndropoulosDBradyKMEasleyRBFraserC. Neuroprotection in pediatric cardiac surgery: what is on the horizon?Prog Pediatr Cardiol. 2010;29(2):113–122.
54.
WypijDNewburgerJWRappaportLA. The effect of duration of deep hypothermic circulatory arrest in infant heart surgery on late neurodevelopment: the Boston Circulatory Arrest Trial. J Thorac Cardiovasc Surg. 2003;126(5):1397–1403.
55.
AndropoulosDBAhmadHBHaqT. The association between brain injury, perioperative anesthetic exposure, and 12-month neurodevelopmental outcomes after neonatal cardiac surgery: a retrospective cohort study. Paediatr Anaesth. 2014;24(3):266–274.
56.
van der PollTLeviM. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10(5):632–638.
57.
LeviMPollT. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41(1):9–15.
58.
van den HengelLGVersteegHH. Tissue factor signaling: a multi-faceted function in biological processes. Front Biosci (Schol Ed). 2011;3:1500–1510.
59.
RothmeierASRufW. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34(1):133–149.
60.
JenneweinCPaulusPZacharowskiK. Linking inflammation and coagulation: novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol. 2011;24(4):375–380.
61.
HosokawaKOhnishiTMiuraN. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res. 2014;133(1):66–72.
62.
YanagidaYGandoSSawamuraA. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery. 2013;154(1):48–57.
63.
FeindtPLitmatheJBoekenUGamsE. Anticoagulation during extracorporeal circulation under conditions of an ongoing systemic inflammatory response syndrome: effects of heparin. Perfusion. 2005;20(1):11–15.
64.
YuXLarsenBRutledgeJ. The profile of the systemic inflammatory response in children undergoing ventricular assist device support. Interact Cardiovasc Thorac Surg. 2012;15(3):426–431.
65.
KatoTSSchulzePCYangJ. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant. 2012;31(1):1–8.
66.
LangdellRDWagnerRHBrinkhousKM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med. 1953;41(4):637–647.
67.
KamalAHTefferiAPruthiRK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007;82(7):864–873.
68.
Bernet-BuettikerVWaldvogelKCannizzaroVAlbisettiM. Antithrombin activity in children with chylothorax. Eur J Cardiothorac Surg. 2006;29(3):406–409.
69.
AndrewMMassicotte-NolanPMitchellLCassidyK. Dysfunctional antithrombin III in sick premature infants. Pediatr Res. 1985;19(2):237–239.
70.
NieblerRAChristensenMBerensRWellnerHMikhailovTTweddellJS. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organ. 2011;35(11):1024–1028.
71.
ByrnesJWSwearingenCJProdhanPFiserRDyamenahalliU. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life. ASAIO J. 2014;60(1):57–62.
72.
HattersleyPG. Activated coagulation time of whole blood. JAMA. 1966;196(5):436–440.
73.
WasowiczMSrinivasCMeineriMBanksBMcCluskeySAKarkoutiK. Technical report: analysis of citrated blood with thromboelastography: comparison with fresh blood samples. Can J Anaesth. 2008;55(5):284–289.
74.
MiaoXLiuJZhaoM. The influence of cardiopulmonary bypass priming without FFP on postoperative coagulation and recovery in pediatric patients with cyanotic congenital heart disease. Eur J Pediatr. 2014;173(11):1437–1443.
75.
NieblerRAGillJCBrabantCP. Thromboelastography in the assessment of bleeding following surgery for congenital heart disease. World J Pediatr Congenit Heart Surg. 2012;3(4):433–438.
76.
RomlinBSWåhlanderHBerggrenH. Intraoperative thromboelastometry is associated with reduced transfusion prevalence in pediatric cardiac surgery. Anesth Analg. 2011;112(1):30–36.
77.
VogelAMRadwanZACoxCSJrCottonBA. Admission rapid thrombelastography delivers real-time “actionable” data in pediatric trauma. J Pediatr Surg. 2013;48(6):1371–1376.
78.
JacksonGNAshpoleKJYentisSM. The TEG vs the ROTEM thromboelastography/thromboelastometry systems. Anaesthesia. 2009;64(2):212–215.
79.
ObengEAHarneyKMMonizTArnoldANeufeldEJTrenorCC III. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr. 2015;166(1):144–150.
80.
WilkeTTeschSScholzAKohlmannTGreinacherA. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost. 2009;7(5):766–773.
81.
LeeGMArepallyGM. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013;2013:668–674.
82.
WirthSMMacaulayTEArmitsteadJASteinkeDTBlechnerMDLewisDA. Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia. J Oncol Pharm Pract. 2010;16(3):161–166.
83.
LinkinsLADansALMooresLK. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S–e530S.
84.
WarkentinTE. Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. Chest. 2012;142(4):815–816.
